Brief: Optinose Announces 3-Month Extension Of FDA Review Period For The Supplemental New Drug Application For Xhance
06/12/2023 13:23
Dec 6 (Reuters) - OptiNose Inc OPTN.O :
* OPTINOSE ANNOUNCES 3-MONTH EXTENSION OF FDA REVIEW PERIOD
FOR
THE SUPPLEMENTAL NEW DRUG APPLICATION FOR XHANCE
* OPTINOSE INC: UPDATED PRESCRIPTION DRUG USER FEE ACT
(PDUFA)
GOAL DATE IS MARCH 16, 2024
Source text for Eikon: ID:nGNX71jfXD
Further company coverage: OPTN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on OptiNose
See all newsOptiNose Inc reports results for the quarter ended March 31 - Earnings Summary
OptiNose Inc expected to post a loss of 74 cents a share - Earnings Preview
Brief: OptiNose Q4 Income From Operations USD 354 Thousand
U.S. RESEARCH ROUNDUP-Darden Restaurants, Nike, Optinose
U.S. STOCKS ON THE MOVE-Accenture, Nike, FedEx